17-43067629-T-C

Variant summary

Our verdict is Pathogenic. The variant received 20 ACMG points: 20P and 0B. PS3PM1PM2PM5PP3_ModeratePP5_Very_Strong

The NM_007294.4(BRCA1):​c.5053A>G​(p.Thr1685Ala) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). ClinVar reports functional evidence for this variant: "SCV000076762: Experimental studies have shown that this missense change affects BRCA1 function (PMID:20516115, 27272900).; SCV005395176: At least one functional study reports experimental evidence evaluating an impact on protein function and showed a damaging effect of this variant on homology directed repair (HDR) activity (e.g. Findlay_2018). PMID:30209399, 38439815, 29446198; SCV005373669: Experimental studies have shown that this missense change affects BRCA1 function (Findlay et al., 2018; Thouvenot et al., 2016; Lee et al., 2010).; SCV000213512: Multiple functional studies have found this variant to be non-functional including a phosphopeptide binding assay; a binding specificity assay; a protease sensitivity assay; a homology-directed DNA repair assay, and a haploid cell survival assay (Lee MS et al. Cancer Res. 2010 Jun;70(12):4880-90; Petitalot A et al. Mol Cancer Res, 2019 01;17:54-69; Findlay GM et al. Nature, 2018 10;562:217-222).; SCV004360135: Multiple functional studies have reported the mutant protein to be non-functional in a phosphopeptide binding assay, a homology-directed DNA repair assay, and cell growth/survival assay (PMID:20516115, 27272900, 30209399, 30257991).; SCV000210194: Published functional studies demonstrate a damaging effect with respect to: stability, binding activity and specificity, transcription activity, and protease sensitivity (Lee 2010, Thouvenot 2016, Woods 2016, Findlay 2018, Fernandes 2019);". Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T1685S) has been classified as Uncertain significance.

Frequency

Genomes: not found (cov: 30)

Consequence

BRCA1
NM_007294.4 missense

Scores

8
9
1

Clinical Significance

Pathogenic reviewed by expert panel P:9U:1

Conservation

PhyloP100: 4.79

Publications

35 publications found
Variant links:
Genes affected
BRCA1 (HGNC:1100): (BRCA1 DNA repair associated) This gene encodes a 190 kD nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The BRCA1 gene contains 22 exons spanning about 110 kb of DNA. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2020]
BRCA1 Gene-Disease associations (from GenCC):
  • BRCA1-related cancer predisposition
    Inheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
  • breast-ovarian cancer, familial, susceptibility to, 1
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • Fanconi anemia, complementation group S
    Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: G2P, ClinGen, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • pancreatic cancer, susceptibility to, 4
    Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
  • hereditary breast ovarian cancer syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Fanconi anemia
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Pathogenic. The variant received 20 ACMG points.

PS3
PS3 evidence extracted from ClinVar submissions: SCV000076762: Experimental studies have shown that this missense change affects BRCA1 function (PMID: 20516115, 27272900).; SCV005395176: At least one functional study reports experimental evidence evaluating an impact on protein function and showed a damaging effect of this variant on homology directed repair (HDR) activity (e.g. Findlay_2018). PMID: 30209399, 38439815, 29446198; SCV005373669: Experimental studies have shown that this missense change affects BRCA1 function (Findlay et al., 2018; Thouvenot et al., 2016; Lee et al., 2010).; SCV000213512: Multiple functional studies have found this variant to be non-functional including a phosphopeptide binding assay; a binding specificity assay; a protease sensitivity assay; a homology-directed DNA repair assay, and a haploid cell survival assay (Lee MS et al. Cancer Res. 2010 Jun;70(12):4880-90; Petitalot A et al. Mol Cancer Res, 2019 01;17:54-69; Findlay GM et al. Nature, 2018 10;562:217-222).; SCV004360135: Multiple functional studies have reported the mutant protein to be non-functional in a phosphopeptide binding assay, a homology-directed DNA repair assay, and cell growth/survival assay (PMID: 20516115, 27272900, 30209399, 30257991).; SCV000210194: Published functional studies demonstrate a damaging effect with respect to: stability, binding activity and specificity, transcription activity, and protease sensitivity (Lee 2010, Thouvenot 2016, Woods 2016, Findlay 2018, Fernandes 2019);
PM1
In a hotspot region, there are 22 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 11 benign, 78 uncertain in NM_007294.4
PM2
Very rare variant in population databases, with high coverage;
PM5
Other missense variant is known to change same aminoacid residue: Variant chr17-43067628-G-A is described in ClinVar as Pathogenic. ClinVar VariationId is 55365.Status of the report is reviewed_by_expert_panel, 3 stars.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.868
PP5
Variant 17-43067629-T-C is Pathogenic according to our data. Variant chr17-43067629-T-C is described in ClinVar as Pathogenic. ClinVar VariationId is 55364.Status of the report is reviewed_by_expert_panel, 3 stars.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_007294.4. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
BRCA1
NM_007294.4
MANE Select
c.5053A>Gp.Thr1685Ala
missense
Exon 16 of 23NP_009225.1P38398-1
BRCA1
NM_001407581.1
c.5119A>Gp.Thr1707Ala
missense
Exon 17 of 24NP_001394510.1A0A2R8Y7V5
BRCA1
NM_001407582.1
c.5119A>Gp.Thr1707Ala
missense
Exon 17 of 24NP_001394511.1A0A2R8Y7V5

Ensembl Transcripts

Sel.
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
BRCA1
ENST00000357654.9
TSL:1 MANE Select
c.5053A>Gp.Thr1685Ala
missense
Exon 16 of 23ENSP00000350283.3P38398-1
BRCA1
ENST00000471181.7
TSL:1
c.5116A>Gp.Thr1706Ala
missense
Exon 17 of 24ENSP00000418960.2P38398-7
BRCA1
ENST00000470026.6
TSL:1
c.5053A>Gp.Thr1685Ala
missense
Exon 16 of 23ENSP00000419274.2P38398-1

Frequencies

GnomAD3 genomes
Cov.:
30
GnomAD4 exome
Cov.:
30
GnomAD4 genome
Cov.:
30
Alfa
AF:
0.00
Hom.:
0

ClinVar

ClinVar submissions
Significance:Pathogenic
Revision:reviewed by expert panel
View on ClinVar
Pathogenic
VUS
Benign
Condition
4
1
-
Breast-ovarian cancer, familial, susceptibility to, 1 (5)
2
-
-
Hereditary breast ovarian cancer syndrome (2)
2
-
-
Hereditary cancer-predisposing syndrome (2)
1
-
-
not provided (1)

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.52
BayesDel_addAF
Pathogenic
0.42
D
BayesDel_noAF
Pathogenic
0.36
CADD
Uncertain
24
DANN
Uncertain
1.0
DEOGEN2
Benign
0.40
T
Eigen
Uncertain
0.64
Eigen_PC
Uncertain
0.61
FATHMM_MKL
Uncertain
0.92
D
LIST_S2
Uncertain
0.93
D
M_CAP
Pathogenic
0.75
D
MetaRNN
Pathogenic
0.87
D
MetaSVM
Uncertain
0.73
D
MutationAssessor
Pathogenic
3.3
M
PhyloP100
4.8
PrimateAI
Uncertain
0.67
T
PROVEAN
Uncertain
-4.0
D
REVEL
Pathogenic
0.88
Sift
Pathogenic
0.0
D
Sift4G
Pathogenic
0.0
D
Polyphen
0.53
P
Vest4
0.89
MVP
0.95
MPC
0.083
ClinPred
0.97
D
GERP RS
5.2
Varity_R
0.96
gMVP
0.87
Mutation Taster
=0/100
disease causing (ClinVar)

Splicing

Name
Calibrated prediction
Score
Prediction
Splicevardb
2.0
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs80356890; hg19: chr17-41219646; API
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.